LRRC41

Summary

LRRC41 (leucine rich repeat containing 41, HGNC:16917) is a protein-coding gene on chromosome 1p34.1-p33, encoding Leucine-rich repeat-containing protein 41 (Q15345). Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.

Predicted to enable identical protein binding activity. Predicted to be involved in protein ubiquitination. Located in membrane.

Source: NCBI Gene 10489 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 320 total — 2 likely-pathogenic
• MANE Select transcript: NM_006369

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16917
Approved symbol	LRRC41
Name	leucine rich repeat containing 41
Location	1p34.1-p33
Locus type	gene with protein product
Status	Approved
Aliases	MUF1
Ensembl gene	ENSG00000132128
Ensembl biotype	protein_coding
OMIM	618753
Entrez	10489

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 12 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000343304, ENST00000469150, ENST00000472710, ENST00000496156, ENST00000498402, ENST00000615587, ENST00000617190, ENST00000866618, ENST00000866619, ENST00000866620, ENST00000866621, ENST00000932747, ENST00000932748, ENST00000949329, ENST00000949330

RefSeq mRNA: 1 — MANE Select: NM_006369 NM_006369

CCDS: CCDS533

Canonical transcript exons

ENST00000617190 — 10 exons

Exon	Start	End
ENSE00001891163	46303124	46303616
ENSE00003525800	46285362	46286499
ENSE00003596247	46297563	46297633
ENSE00003713599	46280192	46280290
ENSE00003717153	46279182	46279257
ENSE00003723151	46281125	46281385
ENSE00003729312	46298284	46298370
ENSE00003735550	46280396	46280560
ENSE00003740610	46279492	46279614
ENSE00003750750	46277462	46279084

Expression profiles

Bgee: expression breadth ubiquitous, 281 present calls, max score 94.66.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 42.5179 / max 292.0406, expressed in 1813 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
12175	20.0007	1792
12172	10.7791	1759
12176	7.2088	1759
12174	1.9825	1364
12173	0.9981	760
12178	0.9101	602
12177	0.4983	260
12171	0.1403	42

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	94.66	gold quality
left uterine tube	UBERON:0001303	94.61	gold quality
adenohypophysis	UBERON:0002196	94.61	gold quality
stromal cell of endometrium	CL:0002255	94.57	gold quality
right ovary	UBERON:0002118	94.45	gold quality
body of uterus	UBERON:0009853	94.18	gold quality
left ovary	UBERON:0002119	94.17	gold quality
endocervix	UBERON:0000458	94.04	gold quality
right adrenal gland cortex	UBERON:0035827	93.96	gold quality
pituitary gland	UBERON:0000007	93.79	gold quality
ectocervix	UBERON:0012249	93.75	gold quality
right adrenal gland	UBERON:0001233	93.63	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	93.60	gold quality
lower esophagus muscularis layer	UBERON:0035833	93.59	gold quality
lower esophagus	UBERON:0013473	93.58	gold quality
left lobe of thyroid gland	UBERON:0001120	93.52	gold quality
left adrenal gland cortex	UBERON:0035825	93.52	gold quality
right lobe of thyroid gland	UBERON:0001119	93.49	gold quality
left adrenal gland	UBERON:0001234	93.47	gold quality
popliteal artery	UBERON:0002250	93.35	gold quality
tibial artery	UBERON:0007610	93.35	gold quality
mucosa of stomach	UBERON:0001199	93.34	gold quality
apex of heart	UBERON:0002098	93.31	gold quality
muscle layer of sigmoid colon	UBERON:0035805	93.28	gold quality
right coronary artery	UBERON:0001625	93.27	gold quality
gastrocnemius	UBERON:0001388	93.26	gold quality
adrenal cortex	UBERON:0001235	93.07	gold quality
aorta	UBERON:0000947	93.01	gold quality
ventricular zone	UBERON:0003053	92.99	gold quality
smooth muscle tissue	UBERON:0001135	92.98	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.59

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

41 targeting LRRC41, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-148A-3P	99.74	73.77	1700
HSA-MIR-148B-3P	99.74	73.75	1700
HSA-MIR-152-3P	99.74	73.75	1703
HSA-MIR-378G	99.71	64.90	1106
HSA-MIR-548M	99.70	68.87	1749
HSA-MIR-488-3P	99.61	68.79	1731
HSA-MIR-6861-3P	99.60	68.46	444
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-3136-3P	99.57	66.59	781
HSA-MIR-7155-3P	99.57	66.48	794
HSA-MIR-186-3P	99.51	66.24	1685
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-6507-5P	99.36	70.46	2524
HSA-MIR-542-3P	99.34	67.58	1270
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-1909-3P	99.03	66.56	1662
HSA-MIR-1294	98.91	69.26	1030
HSA-MIR-9986	98.91	69.28	1024
HSA-MIR-3922-5P	98.77	66.53	1059
HSA-MIR-7977	98.65	66.18	2590
HSA-MIR-9500	98.62	66.54	1845
HSA-MIR-3187-5P	98.36	65.74	1776
HSA-MIR-92A-1-5P	98.28	64.51	631

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	lrrc41	ENSDARG00000096306
mus_musculus	Lrrc41	ENSMUSG00000028703
rattus_norvegicus	Lrrc41	ENSRNOG00000013642

Protein

Protein identifiers

Leucine-rich repeat-containing protein 41 — Q15345 (reviewed: Q15345)

Alternative names: Protein Muf1

All UniProt accessions (5): Q15345, A0A087WTI9, A0A087WTU1, A0A087X0S7, A0A0B4J2G4

UniProt curated annotations — full annotation on UniProt →

Function. Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.

Subunit / interactions. Part of an E3 ubiquitin-protein ligase complex with Elongin BC (ELOB and ELOC), RBX1 and CUL5. Component of a probable ECS(LRRC41) complex which contains CUL5, RNF7/RBX2, Elongin BC and LRRC41. Interacts with CUL5, RNF7, ELOB and ELOC.

Domain organisation. The Elongin BC complex binding domain is also known as BC-box with the consensus [APST]-L-x(3)-C-x(3)-[AILV].

Pathway. Protein modification; protein ubiquitination.

Isoforms (2)

UniProt ID	Names	Canonical?
Q15345-2	2	yes
Q15345-3	3

RefSeq proteins (1): NP_006360* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026137	Leu_rpt_41	Family
IPR032675	LRR_dom_sf	Homologous_superfamily

UniProt features (24 total): repeat 7, modified residue 6, sequence conflict 3, compositionally biased region 2, splice variant 2, region of interest 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15345-F1	71.96	0.30

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 155, 276, 326, 327, 357, 373

Function

Pathways and Gene Ontology

Reactome pathways

10 pathways

ID	Pathway
R-HSA-8951664	Neddylation
R-HSA-9706019	RHOBTB3 ATPase cycle
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation
R-HSA-1280218	Adaptive Immune System
R-HSA-162582	Signal Transduction
R-HSA-168256	Immune System
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3
R-HSA-983169	Class I MHC mediated antigen processing & presentation

MSigDB gene sets: 161 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_DN, CCAWYNNGAAR_UNKNOWN, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, TGACCTY_ERR1_Q2, YY1_Q6, WANG_LMO4_TARGETS_DN, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, ELK1_01, NRF2_01, NERF_Q2, CETS1P54_01

GO Biological Process (1): protein ubiquitination (GO:0016567)

GO Molecular Function (2): identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-7 pathways:

Category	Pathways
Post-translational protein modification	1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Class I MHC mediated antigen processing & presentation	1
Immune System	1
Metabolism of proteins	1
Signal Transduction	1
Adaptive Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
protein modification by small protein conjugation	1
protein binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

512 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LRRC41	CUL5	Q93034	764
LRRC41	ELOA2	Q8IYF1	629
LRRC41	ELOA	Q14241	592
LRRC41	RBX1	P62877	581
LRRC41	WSB1	Q9Y6I7	447
LRRC41	SPSB4	Q96A44	395
LRRC41	WSB2	Q9NYS7	381
LRRC41	TRIM73	Q86UV7	377
LRRC41	RHOBTB3	O94955	373
LRRC41	ZC3H15	Q8WU90	372
LRRC41	TEX261	Q6UWH6	370
LRRC41	RAB40A	Q8WXH6	370
LRRC41	RNF113B	Q8IZP6	357
LRRC41	CUL2	Q13617	352
LRRC41	UBN1	Q9NPG3	348
LRRC41	TRIM74	Q86UV6	348

IntAct

62 interactions, top by confidence:

A	B	Type	Score
CUL5	SOCS2	psi-mi:“MI:0914”(association)	0.880
EXOC8	EXOC5	psi-mi:“MI:0914”(association)	0.730
CUL5	SOCS6	psi-mi:“MI:0914”(association)	0.640
LRRC41	SMUG1	psi-mi:“MI:0915”(physical association)	0.560
KRT34	LRRC41	psi-mi:“MI:0915”(physical association)	0.560
KRT31	LRRC41	psi-mi:“MI:0915”(physical association)	0.560
CYSRT1	LRRC41	psi-mi:“MI:0915”(physical association)	0.560
LRRC41	FHL5	psi-mi:“MI:0915”(physical association)	0.560
LRRC41	KRTAP6-2	psi-mi:“MI:0915”(physical association)	0.560
LRRC41	KRTAP3-1	psi-mi:“MI:0915”(physical association)	0.560
BPNT1	GTPBP10	psi-mi:“MI:0914”(association)	0.530
PPP3CC	NFATC1	psi-mi:“MI:0914”(association)	0.530
SPCS3	ENTPD6	psi-mi:“MI:0914”(association)	0.530
DRG1	LRRC41	psi-mi:“MI:0914”(association)	0.530
RNF7	SOCS7	psi-mi:“MI:0914”(association)	0.530
DDI2	LRRC41	psi-mi:“MI:0915”(physical association)	0.400
LRRC41	RBPMS	psi-mi:“MI:0915”(physical association)	0.370
CPSF3	P4HA2	psi-mi:“MI:0914”(association)	0.350
TEAD2	DDX39A	psi-mi:“MI:0914”(association)	0.350
RIPK4	VWA8	psi-mi:“MI:0914”(association)	0.350
DCUN1D1	RGSL1	psi-mi:“MI:0914”(association)	0.350
CUL5	DDX3X	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
rep	TBKBP1	psi-mi:“MI:0914”(association)	0.350
MAST1	ZSWIM8	psi-mi:“MI:0914”(association)	0.350
LDLRAD1	GXYLT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (109): LRRC41 (Affinity Capture-RNA), LRRC41 (Affinity Capture-MS), LRRC41 (Affinity Capture-MS), LRRC41 (Affinity Capture-MS), LRRC41 (Affinity Capture-MS), RBPMS (Two-hybrid), LRRC41 (Affinity Capture-MS), LRRC41 (Affinity Capture-MS), LRRC41 (Affinity Capture-MS), LRRC41 (Affinity Capture-MS), LRRC41 (Affinity Capture-MS), LRRC41 (Affinity Capture-MS), LRRC41 (Affinity Capture-MS), LRRC41 (Affinity Capture-MS), LRRC41 (Affinity Capture-MS)

ESM2 similar proteins: A0A140LI67, A0A1W2PR48, A0JP70, D3YYM4, F1LW30, O13034, O15040, O70173, Q15345, Q3SXM0, Q3UDP0, Q3UJB9, Q3ULW6, Q3V129, Q3ZAV8, Q58DC2, Q5F479, Q5JV73, Q5M9H0, Q5M9H1, Q5R6T6, Q5R9H2, Q68DX3, Q6IRN0, Q6NV72, Q6P2E9, Q6P4K6, Q6PCD5, Q6ZPG2, Q6ZW76, Q7TNH6, Q80TQ5, Q8BLD6, Q8C008, Q8C5V5, Q8CBW4, Q8CIK8, Q8IWE5, Q8JZL1, Q8K1C9

Diamond homologs: Q0P5G1, Q15345, Q29RR1, Q5M9H1, Q5R9H2, Q8K1C9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

320 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	2
Uncertain significance	218
Likely benign	76
Benign	1

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
929735	NM_003579.4(RAD54L):c.1883A>C (p.Glu628Ala)	Likely pathogenic
929736	NM_003579.4(RAD54L):c.1900C>T (p.Arg634Cys)	Likely pathogenic

SpliceAI

3640 predictions. Top by Δscore:

Variant	Effect	Δscore
1:46261259:A:AG	acceptor_gain	1.0000
1:46261259:AGAAG:A	acceptor_gain	1.0000
1:46261260:G:GA	acceptor_gain	1.0000
1:46261260:GAA:G	acceptor_gain	1.0000
1:46261260:GAAGG:G	acceptor_gain	1.0000
1:46261357:G:GT	donor_gain	1.0000
1:46261357:G:T	donor_gain	1.0000
1:46261381:ACGAG:A	donor_gain	1.0000
1:46267563:GCT:G	donor_gain	1.0000
1:46267565:T:G	donor_gain	1.0000
1:46267565:T:TG	donor_gain	1.0000
1:46267578:C:G	donor_gain	1.0000
1:46270657:AG:A	acceptor_gain	1.0000
1:46270658:GG:G	acceptor_gain	1.0000
1:46270781:AATAG:A	donor_gain	1.0000
1:46272751:A:G	donor_gain	1.0000
1:46272803:G:GG	donor_gain	1.0000
1:46274533:TCCA:T	acceptor_loss	1.0000
1:46274534:CCA:C	acceptor_loss	1.0000
1:46274536:A:AG	acceptor_gain	1.0000
1:46274536:AG:A	acceptor_loss	1.0000
1:46274537:G:GG	acceptor_gain	1.0000
1:46274537:G:GT	acceptor_loss	1.0000
1:46274537:GA:G	acceptor_gain	1.0000
1:46274537:GAGC:G	acceptor_gain	1.0000
1:46274537:GAGCC:G	acceptor_gain	1.0000
1:46274681:TCAA:T	donor_gain	1.0000
1:46274687:G:GT	donor_gain	1.0000
1:46274714:GTCT:G	donor_gain	1.0000
1:46274718:G:GG	donor_gain	1.0000

AlphaMissense

5178 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:46278988:G:C	N772K	1.000
1:46278988:G:T	N772K	1.000
1:46279049:A:G	F752S	1.000
1:46279078:G:C	N742K	1.000
1:46279078:G:T	N742K	1.000
1:46279499:G:C	N712K	1.000
1:46279499:G:T	N712K	1.000
1:46279595:G:C	C680W	1.000
1:46279598:G:C	F679L	1.000
1:46279598:G:T	F679L	1.000
1:46279600:A:G	F679L	1.000
1:46285379:A:G	L493P	1.000
1:46285398:A:G	W487R	1.000
1:46285398:A:T	W487R	1.000
1:46286107:A:C	S250R	1.000
1:46286107:A:T	S250R	1.000
1:46286109:T:G	S250R	1.000
1:46286258:A:G	F200S	1.000
1:46286357:A:G	L167P	1.000
1:46297613:A:G	W103R	1.000
1:46297613:A:T	W103R	1.000
1:46278890:A:G	F805S	0.999
1:46278909:A:G	W799R	0.999
1:46278909:A:T	W799R	0.999
1:46278941:A:G	L788P	0.999
1:46278954:C:G	A784P	0.999
1:46278989:T:A	N772I	0.999
1:46278990:T:G	N772H	0.999
1:46279058:A:G	L749P	0.999
1:46279058:A:T	L749H	0.999

dbSNP variants (sampled 300 via entrez): RS1000072834 (1:46277559 G>A), RS1000106401 (1:46302431 C>A,G,T), RS1000153699 (1:46287147 C>A,G,T), RS1000281674 (1:46283748 C>T), RS1000434365 (1:46290700 G>A,C), RS1000468251 (1:46289595 T>C), RS1000592280 (1:46282746 A>C), RS1000657406 (1:46283953 T>C), RS1000698215 (1:46295636 T>C), RS1000720514 (1:46289425 C>A,T), RS1000821225 (1:46289773 G>A), RS1000970026 (1:46282727 A>G), RS1001004742 (1:46302306 C>G,T), RS1001034237 (1:46302015 A>C,G), RS1001162734 (1:46303267 G>A,T)

Disease associations

OMIM: gene MIM:618753 | disease phenotypes: MIM:193100

GenCC curated gene-disease

Mondo (3): autosomal dominant hypophosphatemic rickets (MONDO:0008660), non-Hodgkin lymphoma (MONDO:0018908), primary ovarian failure (MONDO:0005387)

Orphanet (3): Autosomal dominant hypophosphatemic rickets (Orphanet:89937), Non-Hodgkin lymphoma (Orphanet:547), NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005951_37	Body mass index	8.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D008228	Lymphoma, Non-Hodgkin	C04.557.386.480; C15.604.515.569.480; C20.683.515.761.480
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750
C562791	Hypophosphatemic Rickets, Autosomal Dominant (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	5
trichostatin A	affects expression, decreases expression	2
sodium arsenite	increases abundance, increases expression, affects cotreatment	2
FR900359	affects phosphorylation	1
2,4,6-tribromophenol	decreases expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
beta-lapachone	increases expression	1
tetrabromobisphenol A	decreases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
monomethylarsonous acid	increases expression	1
K 7174	increases expression	1
fenpyroximate	decreases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	decreases expression	1
ICG 001	increases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
picoxystrobin	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Bortezomib	decreases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Antimycin A	decreases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Benzo(a)pyrene	affects methylation	1
Caffeine	affects phosphorylation	1
Cisplatin	decreases expression	1
Cytarabine	decreases expression	1
Ketoconazole	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1W4	Abcam HeLa LRRC41 KO	Cancer cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00090038	PHASE4	COMPLETED	Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin’s Lymphoma
NCT00162955	PHASE4	COMPLETED	Prevention of CHOP-induced Chronic Cardiotoxicity
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00352703	PHASE4	COMPLETED	PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
NCT00430352	PHASE4	COMPLETED	MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin’s Lymphoma.
NCT00797810	PHASE4	UNKNOWN	Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin’s Lymphoma in Adults
NCT00808171	PHASE4	COMPLETED	Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture
NCT00926757	PHASE4	COMPLETED	Prophylactic Use of Entecavir for Non-Hodgkin’s Lymphoma Patients With Resolved Hepatitis B
NCT00969462	PHASE4	COMPLETED	Doxorubicin Pharmacokinetics and Response in Non Hodgkin’s Lymphoma
NCT01124526	PHASE4	COMPLETED	Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma
NCT01164475	PHASE4	COMPLETED	Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin’s Lymphoma (NHL) Weighing Less Than 70 Kilograms
NCT01180049	PHASE4	COMPLETED	Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
NCT02782845	PHASE4	COMPLETED	An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin’s Lymphoma (NHL)
NCT05191225	PHASE4	UNKNOWN	Ultrafast Truxima Infusion in Non-Hodgkin’s Lymphoma: Txagorapid Study
NCT06665737	PHASE4	NOT_YET_RECRUITING	Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin’s Lymphoma Patients
NCT06876649	PHASE4	RECRUITING	A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876662	PHASE4	RECRUITING	A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
NCT07016165	PHASE4	RECRUITING	Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
NCT00039910	PHASE3	COMPLETED	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00057343	PHASE3	TERMINATED	Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin’s Lymphoma
NCT00078598	PHASE3	UNKNOWN	A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin’s Lymphoma
NCT00091676	PHASE3	UNKNOWN	Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma
NCT00129090	PHASE3	COMPLETED	Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin’s Lymphoma
NCT00133302	PHASE3	TERMINATED	Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin’s Lymphoma (JCOG9809)
NCT00139841	PHASE3	COMPLETED	Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin’s Lymphoma (NHL) Who Are Refractory to Rituximab
NCT00145652	PHASE3	COMPLETED	Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders.
NCT00152139	PHASE3	COMPLETED	Stem Cell Transplantation for Patients With Hematologic Malignancies
NCT00269113	PHASE3	COMPLETED	A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin’s Lymphoma
NCT00312845	PHASE3	COMPLETED	Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma
NCT00332202	PHASE3	COMPLETED	PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
NCT00352846	PHASE3	COMPLETED	Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
NCT00398411	PHASE3	COMPLETED	Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
NCT00463463	PHASE3	UNKNOWN	Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin’s Lymphoma
NCT00491491	PHASE3	COMPLETED	Zevalin-beam for Aggressive Lymphoma
NCT00577161	PHASE3	WITHDRAWN	Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
NCT00719472	PHASE3	COMPLETED	A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin’s Lymphoma (RATE)
NCT00877006	PHASE3	COMPLETED	Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
NCT00877214	PHASE3	ACTIVE_NOT_RECRUITING	Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
NCT00928018	PHASE3	COMPLETED	Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
NCT00991211	PHASE3	COMPLETED	Bendamustine Plus Rituximab Versus CHOP Plus Rituximab